“Nerve damage, also known as peripheral neuropathy, can really impact a patient’s everyday living and quality of life,” Associate Professor Louise Nott said.
“This trial – called COMPRES – will help us identify if an intervention like compression therapy can prevent this side effect or minimise its effect on their physical and emotional well-being.”
Co-investigator Georgina Douglas says there is very limited research on preventative interventions to neurotoxic effects for patients treated with Oxaliplatin.
“Peripheral neuropathy is one of the most common side effects related to this particular chemotherapy,” Georgina said.
“It can be very painful for the patient and can also lead to terminating treatment early or reducing the dose.”
“Establishing a cost-effective, minimally invasive way to prevent this side effect would significantly enhance the quality of life for patients undergoing this type of chemotherapy,” Georgina said.
Associate Professor Peter Gorayski and Lydia Tamblyn will lead another innovative research project funded by ICF – a clinical registry study called Innovative Low-dose Radiation for OsteoArthritis Relief and Management (iROAR).
“Our study, iROAR, represents a significant step forward in exploring non-invasive treatment options for osteoarthritis,” Associate Professor Peter Gorayski said.
“By evaluating the safety and efficacy of low-dose radiation therapy (LDRT), we aim to provide valuable data that could lead to improved quality of life for patients suffering from this common condition.
“This research will also contribute to the growing body of real-world evidence, helping us understand how these therapies perform outside the controlled environment of clinical trials.”
Co-investigator Lydia Tamblyn says this registry is important for people with osteoarthritis because it is a potential effective treatment option that could help them feel better without needing surgery or taking medications long-term.
“Osteoarthritis can be very tough to live with, so finding new ways to treat it is crucial,” Lydia said.
“By having this registry, we will establish important relationships that may improve patient access to LDRT into the future.
“It’s a great example of how working together, we can make a real difference in healthcare,” Lydia said.
ICF looks forward to the impact these studies will have on patient treatment and care.
Learn more about our research initiatives Our clinical trials – Icon Cancer Foundation
